Division of Biology and Chemistry (BIO)The Division of Biology and Chemistry at PSI is subdivided into three laboratories pursuing research in the areas of structural biology, bioimaging and radiopharmacy.
Araris Biotech among top 5 in business plan ranking at >>venture2018>>Araris Biotech, a Spin-Off company in foundation from the Center for Radiopharmaceutical Sciences (Prof. Roger Schibli) at the BIO division, has been ranked in the TOP5 in the business plan competition of >>Venture>>. Araris is focusing on the development of a new method for the generation of antibody-drug conjugates (ADCs) with a well-defined, optimal antibody-to-drug ratio. The technology will be used to establish a drug development platform for targeted therapies and diagnostic applications. more info
Biological light sensor filmed in actionUsing X-ray laser technology, a team led by researchers of the Paul Scherrer Institute PSI has recorded one of the fastest processes in biology. In doing so, they produced a molecular movie that reveals how the light sensor retinal is activated in a protein molecule. Such reactions occur in numerous organisms that use the information or energy content of light – they enable certain bacteria to produce energy through photosynthesis, initiate the process of vision in humans and animals, and regulate adaptations to the circadian rhythm. The movie shows for the first time how a protein efficiently controls the reaction of the embedded light sensor. The images, published in the journal Science, were captured at the free-electron X-ray laser LCLS at Stanford University in California. Further investigations are planned at SwissFEL, the new free-electron X-ray laser at PSI. Besides the scientists from Switzerland, researchers from Japan, the USA, Germany, Israel, and Sweden took part in this study. more info
Petersen Investigator award in 2018 goes to the Center for Radiopharmaceutical Sciences at PSIThe Neuroendocrine Tumor Research Foundation (NETRF) is committed to funding the most promising research in order to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers. In January 2018 the Board of Directors has awarded a Petersen Investigator award to the team of Professor Roger Schibli for their research proposal titled, “Simultaneous Auger-Electron and β--Particle Therapy of Metastasized NET Using 161Tb-DOTATOC”. more info